Literature DB >> 34025092

Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon.

Gagan Kaur1, Patrick Baghdasaryan1, Balaji Natarajan1, Prabhdeep Sethi1, Ashis Mukherjee1, Padmini Varadarajan1, Ramdas G Pai1.   

Abstract

Coronary no-reflow phenomenon is a lethal mechanism of ongoing myocardial injury, following successful revascularization of an infarct-related coronary artery. Incidence of this phenomenon is high following percutaneous intervention, and is associated with adverse in-hospital and long-term outcomes. Several mechanisms such as ischemia-reperfusion injury and distal microthromboembolism in genetically susceptible patients and those with preexisting endothelial dysfunction have been implicated. However, the exact mechanism in humans is still poorly understood. Several investigative and treatment strategies within and outside the cardiac catheterization laboratory have been proposed, but have not uniformly shown success in reducing mortality or in preventing adverse left ventricular remodeling resulting from this condition. The aim of this article is to provide a brief and concise review of the current understanding of the pathophysiology, clinical predictors, and investigations and management of coronary no-reflow phenomenon. International College of Angiology. This article is published by Thieme.

Entities:  

Keywords:  angiogram; diagnosis; magnetic resonance imaging; management; no-reflow phenomenon; pathophysiology

Year:  2021        PMID: 34025092      PMCID: PMC8128485          DOI: 10.1055/s-0041-1725979

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  35 in total

1.  Impact of intracoronary adenosine administration during primary PCI: A meta-analysis.

Authors:  Alberto Polimeni; Salvatore De Rosa; Jolanda Sabatino; Sabato Sorrentino; Ciro Indolfi
Journal:  Int J Cardiol       Date:  2015-11-18       Impact factor: 4.164

Review 2.  The no-reflow phenomenon: State of the art.

Authors:  Claire Bouleti; Nathan Mewton; Stéphane Germain
Journal:  Arch Cardiovasc Dis       Date:  2015-11-23       Impact factor: 2.340

3.  A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

Authors:  Allan M Ross; Raymond J Gibbons; Gregg W Stone; Robert A Kloner; R Wayne Alexander
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

Review 4.  Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.

Authors:  Qiang Su; Tun Swe Nyi; Lang Li
Journal:  Cochrane Database Syst Rev       Date:  2015-05-18

5.  Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

Authors:  Holger Thiele; Jochen Wöhrle; Rainer Hambrecht; Harald Rittger; Ralf Birkemeyer; Bernward Lauer; Petra Neuhaus; Oana Brosteanu; Peter Sick; Marcus Wiemer; Sebastian Kerber; Klaus Kleinertz; Ingo Eitel; Steffen Desch; Gerhard Schuler
Journal:  Lancet       Date:  2012-02-21       Impact factor: 79.321

6.  Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms.

Authors:  J A Lima; R M Judd; A Bazille; S P Schulman; E Atalar; E A Zerhouni
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

7.  The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction.

Authors:  T R Porter; S Li; R Oster; U Deligonul
Journal:  Am J Cardiol       Date:  1998-11-15       Impact factor: 2.778

8.  The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention.

Authors:  Shigeo Umemura; Seishi Nakamura; Tetsuro Sugiura; Yoshiaki Tsuka; Keisuke Fujitaka; Susumu Yoshida; Masato Baden; Toshiji Iwasaka
Journal:  Nucl Med Commun       Date:  2006-03       Impact factor: 1.690

9.  Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction.

Authors:  Robert W Harrison; Atul Aggarwal; Fang-shu Ou; Lloyd W Klein; John S Rumsfeld; Matthew T Roe; Tracy Y Wang
Journal:  Am J Cardiol       Date:  2012-10-27       Impact factor: 2.778

Review 10.  The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis.

Authors:  Jonny Karunia Fajar; Teuku Heriansyah; Mohammad Saifur Rohman
Journal:  Indian Heart J       Date:  2018-01-31
View more
  6 in total

Review 1.  Controlling Reperfusion Injury With Controlled Reperfusion: Historical Perspectives and New Paradigms.

Authors:  Demetria M Fischesser; Bin Bo; Rachel P Benton; Haili Su; Newsha Jahanpanah; Kevin J Haworth
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-09-17       Impact factor: 2.457

Review 2.  A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon.

Authors:  Larisa Renata Pantea-Roșan; Simona Gabriela Bungau; Andrei-Flavius Radu; Vlad Alin Pantea; Mădălina Ioana Moisi; Cosmin Mihai Vesa; Tapan Behl; Aurelia Cristina Nechifor; Elena Emilia Babes; Manuela Stoicescu; Daniela Gitea; Diana Carina Iovanovici; Cristiana Bustea
Journal:  Diagnostics (Basel)       Date:  2022-04-08

3.  MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Xin-Tao Zhang; Zhao-Rong Lin; Lin Zhang; Zi-Wen Zhao; Liang-Long Chen
Journal:  BMC Cardiovasc Disord       Date:  2022-03-18       Impact factor: 2.298

4.  Risk Factors for No-Reflow in Patients with ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Case-Control Study.

Authors:  Ying Yu; Yongquan Wu; Xianyi Wu; Jinwen Wang; Changhua Wang
Journal:  Cardiol Res Pract       Date:  2022-03-10       Impact factor: 1.866

Review 5.  "No-Reflow" Phenomenon: A Contemporary Review.

Authors:  Gianmarco Annibali; Innocenzo Scrocca; Tiziana Claudia Aranzulla; Emanuele Meliga; Francesco Maiellaro; Giuseppe Musumeci
Journal:  J Clin Med       Date:  2022-04-16       Impact factor: 4.964

6.  Neutrophil-to-platelet ratio predicts mortality following percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction.

Authors:  Yuhui Lin; Wenjun Dai; Yongquan Chen; Xiaoqing He; Yunhong Xu
Journal:  Front Physiol       Date:  2022-09-19       Impact factor: 4.755

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.